Observation des pharmacodépendances en médecine ambulatoire : le programme OPEMA

Moracchini, Christophe; Orléans, Veronica; Miloudi, Samira; Frauger, Élisabeth; Micallef, Joëlle; Thirion, Xavier

doi:10.2515/therapie/2012037

Cited by 17 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Practitioners, situated within the national borders, will be randomly selected from the list of the National Health Insurance for Wage labourers (Caisse Nationale de l’Assurance Maladie des Travailleurs Salariés (CNAMTS)). Practitioners specialised in the care of addictions and used to working with the FAN will also be solicited 15. Practitioners with an independent practice at the time of change in regulatory framework and who agree to participate, via oral consent, will be included.…”

Section: Methods and Analysismentioning

confidence: 99%

French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol

et al. 2019

View full text Add to dashboard Cite

IntroductionIn recent years, data collected by the French Addictovigilance Network have shown the potential for abuse and addiction associated with zolpidem (the most sold hypnotic drug in France). Since 10 April 2017, new regulations have come into force that require zolpidem to be prescribed on special secure prescription pads, in order to reduce the risk of abuse or misuse. This measure has far-reaching repercussions that are not only limited to the consumption of zolpidem but also extend to the usage of sedative medication on a whole. The objective of the ZOlpidem and the Reinforcement of the Regulation of prescription Orders (ZORRO) study is to evaluate the overall impact of the new regulatory framework requiring zolpidem to be prescribed on special secure prescription pads. Three axes will be evaluated: the number of consumers, the type of consumption (chronic use versus occasional use, problematic consumption versus non-problematic use) and the consumption of other sedative molecules.The study has been registered in the Protocol Registration and Results System under the numberNCT03584542at stage "Pre-results".Methods and analysisThe ZORRO study is an epidemiological, observational, national multicentre, non-controlled, prospective research project supported by the French National Agency for Medicines and Health Products Safety. The evaluation of the impact of the regulatory framework change relative to zolpidem will be done according to two axes: via an epidemiological study of the French National Health Insurance database and by the implementation of field studies of prescribers and consumers of zolpidem.Ethics and disseminationThe Nantes Research Ethics Committee (Groupe Nantais d’Ethique dans le Domaine de la Santé), the Committee for the Protection of the Population and the Committee of Expertise in Research, Studies and Evaluations in the Field of Health approved this study. Results will be presented in national and international conferences and submitted to peer-reviewed journals.Trial registration numberNCT03584542; Pre-results.

show abstract

Section: Methods and Analysismentioning

confidence: 99%

French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Plusieurs NPS ont été récemment inscrits sur En France les données recueillies par le réseau des centres d'addictovigilance [4] montrent une augmentation de la consommation entre 2009 et 2014 (Fig. 1), notamment à travers les enquêtes épidémiologiques transversales annuelles « observation des produits psychotropes illicites ou détournés de leur utilisation médicamenteuse » (OPPIDUM) [5,6], « observation des pharmacodépendances en médecine ambulatoire » (OPEMA) [7], « décès en relation avec l'abus de médicaments et de substances » (DRAMES) [8]; le nombre de cas notifiés de consommation et de complications associées à l'usage de NPS a considérablement augmenté, de 5 cas en 2009 à 81 en 2014. Cependant, on peut supposer que la consommation de ces substances est largement sous-estimée en raison de leur identification difficile sur le plan analytique.…”

Section: Nouveaux Produits De Synthèse Et Données Recueillies Par Le ...unclassified

“…Les consommateurs observés dans les enquêtes OPPIDUM [5,6] et OPEMA [7], ont le plus souvent des ressources financières et un logement, un niveau d'études secondaires et consomment de la MDMA occasionnellement, majoritairement par voie orale. Il s'agit le plus souvent d'hommes de 18 à 46 ans, poly-consommateurs.…”

Section: Nouveaux Produits De Synthèse Et Données Recueillies Par Le ...unclassified

Usages de substances de synthèse en France et en Europe

et al. 2021

View full text Add to dashboard Cite

“…This survey is dedicated to ambulatory care and includes patients consulting on grounds related to abuse/addiction, or presenting with signs of abuse/addiction to psychoactive drugs, or under OSD . This study, which is repeated every year, reveals trends in consumption . The data are pooled with that of another FAN monitoring program called OPPIDUM , which is the equivalent to OPEMA but in specialized addiction structures, via disproportionate analysis, such that the pooled results highlight the medication most at risk .…”

Section: Examples Of the Strong Involvement Of French Gps In Addictovmentioning

confidence: 99%

Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?

Gentile

Jego

Spadari

et al. 2018

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Addictovigilance is a health vigilance dedicated to the survey of medicinal or illicit psychoactive substance use disorders (SUDs). France is the only European country to have a vigilance system specifically dedicated to substances with an abuse/addiction potential. The French Addictovigilance system is organized in a network of regional tertiary centres (called Abuse and Dependence Monitoring Centres, CEIP-Addictovigilance) and works in close collaboration with Regional and National health authorities. Because of the essential and unavoidable nature of their practice in the French Healthcare system, general practitioners (GPs) are key actors to identify and track Addictovigilance signals. They have been involved in several of the pharmacoepidemiological surveys implemented by the French Addictovigilance Network (FAN). Now, they increasingly participate in clinical research projects and studies. In this article, interactions between GPs and the FAN are illustrated with two examples: patients on opioid substitution treatment and patients on opioid analgesics. Collaborations between GPs and the FAN could be further potentiated. In particular, more effective communication on psychoactive SUDs including abuse/addiction is necessary to optimize the implementation of preventive measures for patients on psychoactive substances medications, and to improve the attitudes of GPs and more widely health professionals in the management of any psychoactive user suffering from SUDs. In addition, both adapted training and improved collaborative research could contribute to the optimization (safety, quality) of professional practices.

show abstract

Observation des pharmacodépendances en médecine ambulatoire : le programme OPEMA

Cited by 17 publications

References 3 publications

French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol

French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol

Usages de substances de synthèse en France et en Europe

Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?

Contact Info

Product

Resources

About